Skip to content
Trial Eligibility
Menu

A Phase 1 Study of MVB-101 Administered Intraprostatically in Patients With Localized Prostate Cancer Who Are Scheduled for Radical Prostatectomy

NCT07944508

This study is recruiting at 2 US sites in 2 states, according to its ClinicalTrials.gov record last updated .

Summary

This Phase 1, open-label, non-randomized, multicenter study will evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of MVB-101 administered by direct intraprostatic injection in adults with previously untreated localized adenocarcinoma of the prostate who are scheduled to undergo radical prostatectomy. Participants will receive MVB-101 once weekly for 4 weeks. Part A will use an i3+3 dose-escalation design to evaluate dose levels of 1, 2, 4, and 8 mg and determine the maximum tolerated dose and recommended Phase 2 dose.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

  • Localized Prostate Adenocarcinoma

Eligibility basics and study details

Study type
Interventional
Phase
Phase 1
Ages
18 years and older
Sex
Male
Healthy volunteers
Not accepted
Sponsor
MultiValent Biotherapies, Inc.
Last updated on ClinicalTrials.gov
November 18, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites

Alabama · 1

  • Urology Centers of Alabama · Homewood, AL

Texas · 1

  • Urology San Antonio · San Antonio, TX

Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.